From St. Louis, Missouri, USA:
I have a friend in Brazil (where I am originally from) who has a child with diabetes, and she heard about a new type of insulin that is supposed to be better than the traditional one. However, Brazilian doctors are still conservative about it, and the Brazilian association has not approved it. She also heard that here in the US, this type of insulin is much more accepted and has been used for a long time. Do you know something about this? She is very concerned she is not giving the best possible medication to her child.
I think that the name of the new insulin to which your friend was referring was probably Lantus (insulin glargine). The principal characteristic of this product is that it is released very evenly over the whole twenty four hours. It is usually given at bedtime with the dose calibrated to the morning fasting blood sugar levels. It cannot however be mixed with other insulins. Usually, it is also part of a diabetes regulation program that includes using a very short acting insulin like Humalog or NovoLog given just after meals so as to account of appetite, the premeal blood sugar and the 'carbs' actually consumed. Another advantage of Lantus is that it seems to reduce the incidence of nocturnal hypoglycemia.
[Editor's comment: At the present time [early 2003], Lantus is only available in Germany, the US, the UK, and Ireland. It should be more widely available later this year. WWQ]
Original posting 18 Feb 2003
Posted to Insulin
Last Updated: Tuesday April 06, 2010 15:09:42
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2017. Comments and Feedback.